Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

Other authors

[Gutiérrez A] Servicio Medicina Digestiva, Hospital General Universitario Alicante, Alicante, Spain. IIS Isabial, Hospital General Universitario Alicante, Alicante, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Zapater P] IIS Isabial, Hospital General Universitario Alicante, Alicante, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Unidad Farmacología Clínica, Hospital General Universitario Alicante, Alicante, Spain. Instituto IDIBE, Universidad Miguel Hernández, San Juan de Alicante, Spain. [Ricart E] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Servicio de Medicina Digestiva Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain.[González-Vivó M] Servicio Medicina Digestiva, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. [Gordillo J] Servicio Patología Digestiva, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain. [Olivares D] Servicio Medicina Digestiva, Hospital Universitario Clínico San Carlos, Madrid, Spain. [Piqueras M] Servicio Medicina Digestiva, Hospital de Terrassa, Consorci Sanitari de Terrassa, Barcelona, Spain

Consorci Sanitari de Terrassa

Publication date

2023-05-18T10:29:55Z

2023-05-18T10:29:55Z

2022-02-01



Abstract

Crohn's disease; Immigrant; Inflammatory bowel disease


Enfermedad de Crohn; Inmigrante; Enfermedad inflamatoria del intestino


Malaltia de Crohn; Immigrant; Malaltia inflamatòria intestinal


Background: Previous studies comparing immigrant ethnic groups and native patients with IBD have yielded clinical and phenotypic differences. To date, no study has focused on the immigrant IBD population in Spain. Methods: Prospective, observational, multicenter study comparing cohorts of IBD patients from ENEIDA-registry who were born outside Spain with a cohort of native patients. Results: We included 13,524 patients (1,864 immigrant and 11,660 native). The immigrants were younger (45 ± 12 vs. 54 ± 16 years, p < 0.001), had been diagnosed younger (31 ± 12 vs. 36 ± 15 years, p < 0.001), and had a shorter disease duration (14 ± 7 vs. 18 ± 8 years, p < 0.001) than native patients. Family history of IBD (9 vs. 14%, p < 0.001) and smoking (30 vs. 40%, p < 0.001) were more frequent among native patients. The most prevalent ethnic groups among immigrants were Caucasian (41.5%), followed by Latin American (30.8%), Arab (18.3%), and Asian (6.7%). Extraintestinal manifestations, mainly musculoskeletal affections, were more frequent in immigrants (19 vs. 11%, p < 0.001). Use of biologics, mainly anti-TNF, was greater in immigrants (36 vs. 29%, p < 0.001). The risk of having extraintestinal manifestations [OR: 2.23 (1.92-2.58, p < 0.001)] and using biologics [OR: 1.13 (1.0-1.26, p = 0.042)] was independently associated with immigrant status in the multivariate analyses. Conclusions: Compared with native-born patients, first-generation-immigrant IBD patients in Spain were younger at disease onset and showed an increased risk of having extraintestinal manifestations and using biologics. Our study suggests a featured phenotype of immigrant IBD patients in Spain, and constitutes a new landmark in the epidemiological characterization of immigrant IBD populations in Southern Europe.

Document Type

Article


Published version

Language

English

Publisher

Frontiers Media

Related items

Frontiers in Medicine;9

https://doi.org/10.3389/fmed.2022.823900

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)